Topic: Bariatric Surgery

Eli Lilly is developing Rettatrutide, a new obesity drug that targets three hormones and reportedly leads to a 28% weight loss, comparable to bariatric surgery. While medical professionals call it "game-changing," critics point to side effects like "joy loss," where patients lose interest in food, sex, and other pleasures. The drug is expected to be submitted for FDA approval by the end of the year.

Pfizer is moving forward with a once-a-day GLP-1 weight loss pill following the failure of a twice-a-day version. A producer in the insurance industry notes that some insurers are now preferring bariatric surgery over expensive GLP-1 medications like Ozempic, leading to a lobbying battle between drug makers and surgical device companies.

Emerging data suggests a link between GLP-1 weight loss drugs and increased risks of depression or suicidal ideation, similar to the quadrupled suicide risk seen after bariatric surgery. Experts suggest that removing food as a coping mechanism for emotional regulation can lead to psychological destabilization. Comparisons were made to the addictive nature of Oreos and cocaine, predicting a future wave of litigation against GLP-1 manufacturers.

Dr. Terry Dubrow has raised alarms regarding the use of Ozempic and other semaglutide drugs, linking them to severe intestinal obstructions and pancreatitis. The autopsy of Lisa Marie Presley revealed she died from a small bowel obstruction related to previous bariatric surgery, a condition that may have been exacerbated by weight-loss medication. The rapid mass-market rollout of these drugs through Hollywood influencers is criticized as a dangerous "life-and-death test market."

The American Academy of Pediatrics (AAP) issued new guidelines recommending aggressive early intervention for childhood obesity, including weight loss medications and bariatric surgery for children as young as 12 and 13. Critics argue that these recommendations ignore the role of highly processed foods and the "food pyramid" in the obesity crisis. The rise of drugs like Ozempic is highlighted as part of a growing pharmaceutical trend to treat obesity as a chronic disease rather than a dietary issue.